Under Armour Sales ACCELERATING and 4 Must-Notice Stock Analyses

Pharmacyclics Inc. (NASDAQ:PCYC):  Rodman & Renshaw believe that concerns surrounding, Ibrutinib, from Pharmacyclics Inc.’s, are overblown and old news. The firm said that this uneasiness was specifically addressed at the 2011 ASH analyst meeting. They keep an Outperform rating on their stock.

Don’t Miss: What Will Google Do With Motorola?

Google Inc. (NASDAQ:GOOG):  Since Google reported in-line second quarter operating results, Oppenheimer believes that investors should be confident about the firm’s management of their mobile transition, rather than being overly concerned about mobile cannibalization. The company thinks that these misgivings were what caused the major drag on Google’s stock. They maintain an Outperform rating on their shares.

Madison Square Garden, Inc. (NASDAQ:MSG):   Morgan Stanley sees the sell-off in Madison Square Garden, Inc., as a buying opportunity and views the fourth quarter report as a catalyst. Shares are Overweight rated.

Target Corp. (NYSE:TGT):   After visiting Target management, Morgan Stanley came away with increased confidence in U.S. sales trends driven by RED Card gains and P Fresh grocery remodels. Shares are Overweight rated with a $69 price target.

Under Armour, Inc. (NYSE:UA):   Under Armour, according to Morgan Stanley, has a balanced risk/reward going into the next quarter. Given an accelerating sales growth, improving margins, and footwear success, it is a stock to own for 2012.  Shares are Overweight rated with a $58 price target.

Don’t Miss: Did Verizon Just Drop A HINT About the New iPhone?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.